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ABSTRACT	MORGAN	ALEXIS	CAWTHON:	Patient	Experiences	with	Small-Scale	Pharmacy	Compounding				 Investigators	examined	patients’	use,	knowledge	and	perceptions	of	pharmacy	compounding	at	an	independent	compounding	pharmacy	in	Mandeville,	Louisiana.	Data	were	collected	using	a	self-administered	survey	that	patients	could	complete	in	hard-copy	in	the	pharmacy	or	at	home,	or	online	using	Qualtrics.		Investigators	found	that,	in	some	instances,	patients	who	use	compounded	medications,	or	have	a	member	of	their	household	who	uses	compounded	medications,	may	be	more	knowledgeable	or	have	more	positive	perceptions	of	compounded	medications.	However,	patients	who	did	not	have	experience	with	compounds	were	not	unknowledgeable	about	the	practice	and	did	not	report	any	negative	perceptions	of	compounding.	These	overall	positive	perceptions	and	high	level	of	knowledge	about	compounded	medications	may	be	a	product	of	this	specific	pharmacy,	and	the	culture	that	the	compounding	pharmacist	has	created	there,	but	further,	in-depth,	longitudinal,	quantitative,	and	qualitative	research	is	needed	to	confirm	these	findings.	Furthermore,	research	is	needed	to	determine	if	this	trend	is	seen	in	other	compounding	pharmacies,	and	for	other	pharmacy	services.	Future	confirmation	of	these	findings	has	significant	implications	for	pharmacists,	and	how	
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the	culture	they	create	in	their	pharmacy	can	lead	to	enhanced	knowledge,	positive	perceptions,	and	increased	satisfaction	among	patients.	
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INTRODUCTION		 According	to	the	Food	and	Drug	Administration	(FDA),	prescription	compounding	is	defined	as	“a	practice	in	which	a	licensed	pharmacist,	or…a	person	under	the	supervision	of	a	licensed	pharmacist,	combines,	mixes,	or	alters	ingredients	of	a	drug	to	create	a	medication	tailored	to	the	needs	of	an	individual	patient”	(Food	and	Drug	Administration,	2013).	The	Drug	Quality	and	Security	Act	defines	compounding	as	“the	combining,	admixing,	mixing,	diluting,	pooling,	reconstituting,	or	otherwise	altering	of	a	drug	or	bulk	drug	substance	to	create	a	drug”	(Pharmaceutical	Compounding	Quality	and	Accountability	Act,	2013).	Darrell	Pesta,	a	pharmacist	in	the	Boston	area	describes	it	as	“making	stuff	that	doesn’t	exist,”	and	Scott	Vallee,	a	pharmacist	in	southern	Louisiana	described	it	as	“the	art	and	science	of	creating	personalized	medication	based	on	prescriptions	from	practitioners”	(personal	communications,	December	16,	2014,	March	20,	2015).	Prescription	compounding	is	a	wide	and	varied	field	that	has	grown	in	popularity	in	recent	years,	and	many	of	its	aspects	are	not	as	concrete	and	well	known	as	more	traditional	prescription	dispensing,	as	shown	by	the	multiple	definitions	that	can	be	used	to	describe	the	practice	of	compounding.			 In	the	1800s,	compounding	was	common	practice	for	a	pharmacist,	if	not	the	main	portion	of	his	job.	Then,	in	the	early	1900s,	the	industrial	revolution	hit,	and	medications	began	to	be	produced	in	large	quantities	in	multiple	strengths	and	
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doses	(Peterson,	2014).	This	left	the	pharmacist	with	little	compounding	to	do,	as	there	was	not	much	need	for	individual	medicine	preparations	for	individual	patients.	As	a	result,	prescription	compounding	decreased	in	popularity	and	prevalence	until	about	the	1990s.	At	that	point,	interest	in	compounding	was	rekindled	with	the	growing	demand	for	veterinary	preparations	as	well	as	“Bioidentical	Hormone	Replacement	Therapy,”	also	known	as	BHRT,	for	the	treatment	of	menopause	in	women.	Both	of	these	have	remained	as	major	markets	for	compounded	medications	to	this	day,	with	“upwards	of	two	million	women	in	the	US	[using	compounded	hormones]	on	a	daily	basis	for	relief	of	symptoms	associated	with	menopause	and	perimenopause”	(Benda,	2006).	As	women,	along	with	many	other	demographic	groups,	and	pets	benefitted	for	years	from	the	fact	that	their	medications	could	be	tailored	to	their	needs,	misfortune	struck	the	compounding	industry	in	2012	with	the	fungal	meningitis	outbreak	from	the	New	England	Compounding	Center	(NECC).	Between	May	and	October	of	that	year,	vials	of	compounded	methylprednisolone	injections	were	inadvertently	contaminated	with	the	fungus	and	distributed	to	other	states	(Peterson,	2014).	This	was	not	the	first	contamination	event	to	occur	in	the	field	of	compounding,	but	it	certainly	got	the	most	press	and	media	attention.	As	a	result,	the	reaction	to	compounding	by	the	public	was	not	a	good	one.	Even	today,	more	than	two	years	after	the	cases	occurred,	many	patients	are	wary	of	compounding	and	compounded	medications.			 In	order	to	explore	patient	perspectives	of	compounded	medications,	searches	were	done	in	an	effort	to	identify	previous	studies	of	patients’	experiences	with	compounding—specifically	small-scale	compounding	done	for	individual	
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patients	in	community	pharmacies.	No	studies	were	identified	from	the	patient’s	perspective,	so	the	literature	reviewed	for	this	study	focused	on	the	history	of	compounding	and	the	compounding	regulations	that	have	been	levied	over	the	years.	The	objectives	of	this	study	are:	1. To	describe	the	prevalence	of	compounded	medication	use	by	respondents	in	a	local	community	pharmacy.	2. To	determine	the	types	of	compounds	respondents	use,	as	well	as	why	respondents	use	compounds.	3. To	examine	patient	knowledge	and	familiarity	of	small-scale,	personal	compounding	done	in	a	local	community	pharmacy.	4. To	examine	patient	satisfaction	and	perceptions	of	small-scale,	personal	compounding	done	in	a	local	community	pharmacy.	
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BACKGROUND	
Defining	Compounding		 Compounding	is	a	field	that	is	not	very	well	understood,	much	less	easy	to	define.	There	appears	to	be	a	fine	line	between	compounding	and	manufacturing	of	prescriptions,	as	well	as	questions	about	whether	something	as	simple	as	reconstituting	a	retail	antibiotic	suspension	is	considered	to	be	“compounding.”	According	to	the	American	Society	of	Health-System	Pharmacists	(ASHP),	compounding	is	a	process	where	“a	medicine	has	to	be	created	because	the	strength,	concentration,	or	dosage	form	that	is	needed	for	a	specific	patient	is	not	commercially	available,”	and	is	under	the	supervision	of	state	boards	of	pharmacy,	rather	than	the	federal	government	(Flaker,	2012).	With	this	definition,	simple	processes	like	reconstituting	an	antibiotic	or	mixing	a	Magic	Mouthwash	are	not	a	form	of	compounding	because	the	medications	are	commercially	available	preparations.	Manufacturing,	as	termed	by	ASHP,	is	“the	preparation	of	large	quantities	of	medication	with	a	process	that	is	approved	and	regulated	by	the	U.S.	Food	and	Drug	Administration	(FDA).	Under	this	process,	manufacturers	must	comply	with	federal	quality	and	safety	standards”	(Flaker,	2012).			 Even	when	making	a	medication	specific	for	a	patient,	there	are	certain	criteria	that	must	be	met.	The	compound	must	be	made	for	an	ethical,	approved	use,	only	approved	ingredients	may	be	used,	and	only	certain	amounts	may	be	made	in	a	
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single	sitting	(Allen,	2003).	Medications	can	only	be	compounded	for	a	patient	if	the	medication	that	the	patient	requires	is	not	already	commercially	available,	or	if	what	is	commercially	available	is	not	suitable	for	the	patient.	Allergies	or	adverse	reactions	to	inactive	ingredients	like	dyes,	preservatives,	or	fillers	are	acceptable	uses	for	compounding.	It	can	also	be	used	if	a	specific	dosage	strength	or	dosage	route	is	not	commercially	available,	or	if	the	physician	prescribes	a	medication	in	which	multiple	commercially	available	products	are	combined	into	a	single	capsule	or	cream,	to	be	administered	together	(personal	communication,	March	20,	2015).	There	are	also	medications	that	have	multiple	clinical	uses,	but	only	one	use	is	FDA	approved	as	an	indication.	In	this	case,	a	compound	can	only	be	made	for	the	indicated	use.	For	example,	domperidone	has	a	FDA-approved	use	is	as	a	gastrointestinal	aid	to	increase	GI	movement	and	prevent	nausea	and	vomiting,	but	there	are	studies	that	show	that	it	can	be	used	to	increase	lactation	in	women.	This	however	was	found	to	cause	dangerous	heart	problems	in	nursing	women,	so	the	FDA	removed	it	as	an	acceptable	medication	for	women	who	are	nursing	(Food	and	Drug	Administration,	2013).	As	a	result,	only	prescriptions	for	domperidone	from	gastroenterologists	are	accepted	as	an	appropriate	order	to	compound	the	medication.	Compounds	must	also	consist	entirely	of	approved	ingredients.	The	FDA	Modernization	Act	of	1997	(FDAMA)	legislated	that	“compounding	must	be	done	using	ingredients	that	had	US	Pharmacopeia/National	Formulary	(USP/NF)	monographs,	were	components	of	commercial	products,	or	appeared	on	a	list	of	approved	bulk	drug	substances	that	was	to	be	developed	by	the	FDA”	(Allen,	2003).	Estriol,	an	estrogen	product	used	in	the	treatment	of	menopause,	is	an	ingredient	
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affected	by	this	law.	The	FDA	states	that	only	pharmacies	with	valid	investigational	new	drug	applications	may	compound	medications	containing	the	estrogen	substance	(2013).	Ingredients	that	prove	to	be	difficult	or	potentially	dangerous	to	compound	are	also	not	approved.	Compounding	pharmacists	are	also	limited	to	the	amount	of	a	compound	they	can	make	at	one	time.	Legally,	the	quantity	of	the	compounded	medication	made	is	only	to	be	sufficient	for	the	individual	patient	prescription	for	which	the	physician	wrote.	These	restrictions	are	also	outlined	by	the	FDAMA,	stating	that	a	pharmacist	could	not	compound	drug	products	that	were,	for	intents	and	purposes,	copies	of	commercially	available	products,	drugs	that	could	present	“demonstrable	difficulties	for	compounding,”	and	may	not	use	an	ingredient	that	is	on	a	list	of	ingredients	that	has	been	removed	from	the	market	for	efficacy	or	safety	reasons	(Allen,	2003).	For	this	reason,	compounds	must	be	made	in	small,	patient-specific	batches,	with	no	excess	to	be	saved	for	use	at	a	later	date.		
History	of	Compounding	Regulation		 The	history	of	compounding	regulation	is	much	more	extensive	than	determining	appropriate	ingredients,	uses,	and	quantities.	The	practice	of	compounding	has	been	around	since	the	medieval	times,	when	medications	were	made	of	fats	and	herbs	in	individual	doses,	only	when	requested	by	a	doctor,	for	a	single	patient.	The	late	1700s	and	early	1800s	brought	with	it	the	Industrial	Revolution,	which	put	compounding	largely	on	hold.	The	Industrial	Revolution	saw	the	rise	of	drug	manufacturing	companies,	churning	out	copious	amounts	of	drugs	offered	in	only	one	or	two	strengths,	making	the	process	of	providing	medication	more	standardized	and	economical	than	preparing	individualized	compounds	
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(Petersen,	2014).	In	1820,	the	United	States	Pharmacopoeia	(USP)	was	established	with	the	intent	of	setting	“standards	(for	quality,	strength,	purity)	for	drug	products	that	were	prescribed	by	physicians	and	prepared	(compounded)	by	pharmacists”	(Allen,	2003).		The	USP	was	used	until	the	early	1900s	as	the	standard	for	pharmaceutical	compounding	in	the	United	States,	mainly	with	regard	to	natural	ingredients.	An	official	set	of	quality	and	purity	standards	was	set	for	the	United	States	in	1906	with	the	US	Pharmacopeial	Convention	(USPC),	and	is	still	in	effect	today,	supplemented	by	more	recent	legislation.	Chapters	795,	797,	1075,	and	1160	of	the	USPC	pertain	directly	to	compounding	ingredients	and	practices	for	sterile	and	non-sterile	compounding	(Allen,	2003).	The	Pure	Food	and	Drug	Act	was	also	passed	in	1906,	and	was	designed	to	regulate	the	shift	that	the	pharmaceutical	industry	was	experiencing	from	small-scale	compounding	of	medications	to	large	scale	manufacturing	practices	(Petersen,	2014).			 In	1938,	the	Pure	Food	and	Drug	Act	was	replaced	by	the	Food,	Drug	and	Cosmetic	Act	(FDCA),	which	played	a	large	role	in	setting	up	the	current	US	Food	and	Drug	Administration,	or	FDA	(Pergolizzi	et.	al,	2013).	This	allowed	compounding	to	be	used	as	a	way	for	doctors	to	“special	order”	medications	that	were	not	commercially	available	for	a	patient,	in	order	for	the	patient	to	receive	optimal	dosing.	Pergolizzi	states	that	this	is	when	pediatric	medication	increased	in	popularity,	because	doctors	were	no	longer	tied	to	the	pill-form	dosages	that	were	too	strong	for	infants	(2013).	They	could	have	the	dosages	cut,	or	the	medication	made	into	a	liquid,	in	order	to	facilitate	the	needs	of	the	child.	The	FDCA	also	stated	that	compounding	pharmacies,	unlike	drug	manufacturers,	were	not	under	the	
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regulations	of	the	FDA,	because	they	were	not	actually	manufacturing	drugs,	due	to	the	small	batch	sizes.	Instead,	compounding	pharmacies	were	deemed	to	be	regulated	by	state	boards	of	pharmacy,	unless	a	manufacturing-type	offense	were	committed,	which	would	allow	the	FDA	to	intervene	(Pergolizzi	et.	al,	2013).			 The	1960s	and	70s	opened	up	doors	to	new	types	of	compounding.	As	technology	advanced,	the	possibility	for	medications	to	be	offered	in	single-dose	vials	and	syringes	arose	and	became	very	popular.	By	only	using	a	syringe	or	vial	once,	the	sterility	of	the	drug	could	be	better	guaranteed	than	that	of	a	multi-use	vial.	This	idea	won	favor	among	doctors,	nurses,	and	patients,	and	the	compounding	of	TPNs,	and	repackaging	of	medication	into	single-use	administrations	became	more	of	a	common	practice	(Pergolizzi	et.	al,	2013).	In	the	1990s,	veterinary	compounds	and	Bioidentical	Hormone	Replacement	Therapies	(BHRT)	became	a	hot	new	topic	in	the	compounding	industry.	Veterinarians	had	the	ability	to	write	prescriptions	for	an	animal,	using	human	medications	with	altered	dosages,	fillers,	or	flavorings.	Studies	show	that	the	1990s	are	also	when	people	began	to	spend	more	money	on	their	pets	with	fancy	outfits	and	toys,	specialty	veterinarians,	as	well	as	medications	better	tailored	to	their	animals	(Petersen,	2014).	Petersen	also	shares	that	compounded	hormone	therapy	also	became	more	popular	in	the	90s,	as	it	offered	women,	as	well	as	men,	many	more	hormone	options	than	the	select	few	that	were	commercially	available,	and	physicians	could	more	specifically	target	the	causes	or	symptoms	of	the	patient’s	hormone	imbalances	(2014).			 1992	brought	the	next	round	of	compounding	regulations,	with	the	FDA	publishing	its	first	Compliance	Policy	Guide,	or	CPG.	Because	it	was	published	by	the	
	 9	
FDA,	who	legally	did	not	have	jurisdiction	over	compounding	pharmacies,	the	guide	was	not	enforceable,	but	provided	very	detailed	guidelines	on	expected	procedures	and	practices	in	a	compounding	pharmacy	(Allen,	2003).	Allen	states	that	the	CPG	explained	the	criteria	that	would	classify	a	pharmacy	as	a	manufacturer	versus	a	compounding	pharmacy,	and	would	therefore	make	the	establishment	subject	to	regulation	by	the	FDA,	rather	than	the	state	board	of	pharmacy	(2003).	In	1997,	official	legislation,	by	the	name	of	the	Food	and	Drug	Administration	Modernization	Act	(FDAMA),	was	passed	and	allowed	the	FDA	to	have	a	bigger	role	in	the	regulation	of	compounding,	declaring	it	the	official	regulatory	board,	rather	than	the	state	boards	of	pharmacy	(Petersen,	2014).	With	their	new	authority,	the	FDA	began	to	investigate	pharmacies	that	they	felt	were	“manufacturing	under	the	guise	of	compounding”	(Allen,	2003).	This	was	a	major	change	for	compounding	pharmacies,	and	many	of	them	challenged	the	restrictions,	with	a	few	cases	making	it	to	the	US	Supreme	Court	(Petersen,	2014).	The	passage	of	the	FDAMA	was	helpful	to	compounding	pharmacies	with	regard	to	New	Drug	Applications,	however.	The	Act	declared	that	if	the	new	prescription	is	being	compounded	based	off	of	a	physician’s	orders,	for	a	single	patient,	then	the	new	drug	requirements	do	not	apply	to	that	drug	(Allen,	2003).		The	practice	of	compounding	has	dealt	with	more	than	the	passage	of	a	few	laws	over	the	years	and	has	had	its	share	of	outbreaks	and	media	attention	as	well.	The	first	was	in	2002,	with	a	fungal	meningitis	outbreak	following	the	administration	of	injections	that	were	found	to	be	contaminated	with	Exophiala	dermatitidis	from	a	compounding	pharmacy	in	North	Carolina,	killing	6	patients	
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(Pergolizzi	et.	al,	2013).	The	FDA	has	also	dealt	with	complaints	from	the	drug	manufacturers,	in	regards	to	compounding.	Wyeth	Pharmaceuticals,	the	manufacturers	of	the	commercially	available	hormone	replacement	drugs	Premarin	and	Prempro,	put	pressure	on	the	FDA	to	delve	deeper	into	the	regulations	in	place	regarding	pharmacists	making	BHRT	drugs.	The	manufacturer	argued	that	was	stealing	a	significant	portion	of	their	FDA-regulated	business,	partly	because	those	pharmacies	did	not	have	to	answer	to	FDA	regulation	(Benda,	2008).	At	the	center	of	the	dispute	was	the	term	“bioidentical,”	which	compounding	pharmacies	used	to	describe	their	hormone	replacement	therapies.	The	Endocrine	Society	defines	“bioidentical”	pertaining	to	hormone	compounds	as	“compounds	that	have	exactly	the	same	chemical	and	molecular	structure	as	hormones	that	are	produced	in	the	human	body”	(Files	et.	al,	2011).	Similarly,	the	American	College	of	Obstetricians	and	Gynecologists	(ACOG)	states	that:		Bioidentical	hormones	are	plant-derived	hormones	that	are	chemically	similar	or	structurally	identical	to	those	produced	by	the	body.	Bioidentical	hormones	include	commercially	available	products	approved	by	the	U.S.	Food	and	Drug	Administration	(FDA),	such	as	micron-ized	progesterone	and	estradiol,	as	well	as	compounded	preparations	that	are	not	regulated	by	the	FDA	(2012).		Wyeth	was	arguing	that	compounding	pharmacies	that	were	offering	or	advertising	“bioidentical”	hormone	therapies	were	taking	a	large	portion	of	their	business,	falsely	advertising	the	benefits	of	compounded	hormones	versus	manufactured	ones,	and	because	they	were	not	regulated	by	the	FDA,	were	getting	away	with	it	
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(Benda,	2008).	In	October	of	2005,	Wyeth	Pharmaceuticals	submitted	a	citizen’s	petition	to	the	FDA,	asking	the	FDA,	among	other	things,	to	classify	compounded	BHRT	products	as	“new	drugs,”	making	them	subject	to	all	of	the	same	FDA	criteria	that	Wyeth	was	subject	to	(Benda,	2008).	In	his	article,	William	Benda	states	that	the	petition	asked	for	enforcement	against	pharmacists	that	were	compounding	or	advertising	BHRT	products	and	were	in	violation	of	the	FDCA,	for	investigation	into	whether	compounding	pharmacies	were	dispensing	PPIs	and	facts	and	risk	information	with	their	compounds,	for	compounding	pharmacists	to	be	required	to	disclose	certain	things	on	their	BHRT	labels,	and	for	another	CPG	to	be	issued	discussing	the	concerns	associated	with	BHRT	medications	(2008).	The	petition	made	it	all	the	way	to	the	Supreme	Court,	where	all	of	the	requests	made	by	Wyeth	Pharmaceuticals	were	denied,	particularly	the	one	requesting	that	compounded	BHRTs	be	subject	to	new	drug	testing.	The	court’s	ruling	was	that	“it	would	not	make	sense	to	require	compounded	drugs	created	to	meet	the	unique	needs	of	individual	patients	to	undergo	the	testing	required	for	the	new	drug	approval	process…requiring	such	testing	would	force	pharmacists	to	stop	providing	compounded	drugs”	(Benda,	2008).	Furthermore,	Benda	states	that	many	patients	and	physicians	were	documented	as	being	on	the	side	of	the	compounded	BHRT	prescriptions,	rather	than	the	commercially	available	ones,	like	those	manufactured	by	Wyeth,	among	others	(2008).		The	compounding	industry	remained	outbreak-free	until	2011,	when	multiple	cases	of	Serratia,	caused	by	the	bacteria	Serratia	marcescens,	were	determined	to	have	been	linked	to	contaminated	total	parenteral	nutrition	(TPN)	
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bags	that	were	compounded	by	a	pharmacy	in	Alabama	and	distributed	in	the	surrounding	areas	(Pergolizzi	et.	al,	2013).	In	2012,	there	was	a	multi-state	outbreak	of	endopthalmitis,	traced	back	to	contaminated	vials	of	intraocular	injections	of	bevacizumab,	along	with	the	well-known	fungal	meningitis	outbreak	traced	back	to	the	New	England	Compounding	Center	(NECC)	(Pergolizzi	et.	al,	2013).	The	NECC	contamination	event	is	the	most	influential	of	these	outbreaks,	due	to	the	large	amount	of	media	attention	that	it	got,	and	the	vast	area	that	the	infections	covered.	Because	the	NECC	is	a	manufacturer	of	compounded	medications,	like	the	methylprednisolone	vials	that	were	affected,	its	products	were	shipped	outside	the	states	borders,	putting	more	than	just	the	customers	of	Massachusetts	at	risk	of	infection.	The	NECC	outbreak	received	such	a	significant	amount	of	media	attention	due	to	the	large	number	of	deaths	and	hospitalizations	caused.	The	injections,	contaminated	with	the	Exserohilium	rostratum	fungi,	were	administered	in	the	spinal	cords	of	patients,	giving	the	fungus	access	to	the	meninges,	causing	fungal	meningitis,	which	is	very	difficult	to	treat	(Centers	for	Disease	Control,	2013).	Because	of	the	geographical	spread	of	the	infected	vials,	and	the	prolonged,	intense	media	exposure	that	the	situation	received,	havoc	broke	out	in	the	United	States	for	multiple	months	as	new	cases	popped	up	across	the	nation.		In	response	to	the	chaos	and	worry	that	was	caused	by	the	NECC	event,	the	FDA	issued	the	Drug	Quality	and	Security	Act	(DQSA)	in	2013.	The	legislation	distinguishes	between	a	compounding	pharmacy	and	compounding	manufacturers,	“which	make	sterile	products	without	or	in	advance	of	a	prescription	and	sell	those	products	across	state	lines”	(Food	and	Drug	Administration,	2013).	The	Act	is	
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divided	into	two	sections.	The	first	section,	the	Compounding	Quality	Act	sets	up	a	compliance	system	in	which	compounding	pharmacies	can	voluntarily	deem	themselves	as	“outsourcing	facilities”	and	be	subject	to	the	same	supervision	by	the	FDA	as	pharmaceutical	manufacturers	(Looser,	2013).	Once	registered	as	an	outsourcing	facility,	the	compounding	pharmacy	must	pay	fees	to	the	FDA,	ensure	that	the	labels	on	their	compounded	medications	clearly	indicate	that	the	drug	is	compounded,	along	with	many	other	pieces	of	information	for	the	patient,	and	be	subject	to	risk-based	inspections,	initiated	by	the	contents	of	the	adverse	event	reports	that	the	outsourcing	facilities	are	required	to	submit	(McGuire-Woods,	2013).	The	Act	also	states	that	the	FDA	was	in	the	process	of	developing	a	new	list	of	drugs	that	may	not	be	used	in	compounds,	as	well	as	bulk	ingredients	that	will	be	permitted.	The	second	section	of	the	DQSA	is	the	Drug	Supply	Chain	Security	Act,	which	requires	that	all	manufacturers	put	barcodes	on	their	products	from	the	very	beginning	of	manufacturing.	The	barcode	can	be	used	to	track	products	through	every	step	of	the	manufacturing	process,	as	well	as	through	the	distributing	and	dispensing	steps	(Food	and	Drug	Administration,	2013).	Because	of	all	of	the	events	that	have	occurred	recently,	there	is	an	understandable	possibility	that	consumer	and	public	opinions	of	compounding	have	been	affected.	Between	the	news	coverage	and	the	talk	of	new	legislation	as	a	result	of	a	widespread	compounding	manufacturing	contamination	error,	the	general	public,	along	with	any	healthcare	professional	not	familiar	with	compounding	practices,	received	a	very	biased	and	dramatized	representation	of	the	
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compounding	industry.	The	lasting	effect	of	this	representation	has	yet	to	be	studied.	 	
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METHODS	
Design		 This	study	was	conducted	using	an	observational,	cross-sectional,	descriptive,	non-experimental	survey	design.	A	cross-sectional	study	is	a	method	of	data	collection,	in	which	all	data	are	gathered	at	one	point	in	time,	rather	than	multiple	times	over	an	extended	period	of	time.		
Sample		 The	sample	frame	for	this	study	consisted	of	any	patients,	age	18	or	older,	of	
C	and	C	Drugs	Vital	Care,	an	independent	retail	pharmacy	in	Mandeville,	Louisiana.	This	setting	was	chosen	for	this	study	because,	unlike	the	other	chain	or	independent	pharmacies	in	the	area,	it	offers	compounded	medications.	A	variety	of	patients	use	these	compounded	medications,	including	children,	animals,	men,	women,	and	elderly	patients.	A	total	of	175	paper	surveys	and	1300	links	to	the	electronic	version	of	the	survey	were	made	available	to	patients	of	the	pharmacy.		
Data	Collection		 Before	any	surveys	were	administered,	an	application	for	exempt	status	was	submitted	to	the	University	of	Mississippi	Institutional	Review	Board	(IRB).	The	University	of	Mississippi	IRB	indeed	designated	the	study	as	exempt,	and	surveys	were	then	allowed	to	be	distributed	and	data	to	be	collected.	The	study	offered	two	ways	in	which	to	complete	the	survey:	a	paper	copy	that	could	be	filled	out	while	in	
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the	pharmacy	or	taken	home	and	brought	back	at	the	patient’s	convenience,	and	a	website	address	that	linked	to	the	survey,	generated	using	Qualtrics.	Refer	to	Appendix	A	for	the	survey	questions	that	were	administered.	Each	form	of	the	survey	given	included	a	cover	letter	explaining	the	study,	and	instructions	on	how	to	complete	it.	Refer	to	Appendices	B	and	C	for	these	letters.			 The	first	few	questions	in	the	survey	were	basic	demographic	questions,	such	as	gender,	age,	ethnicity,	education,	employment	status,	and	household	income.	The	survey	also	contained	questions	about	patients’	use,	knowledge	and	perceptions	of	the	small-scale	pharmacy	compounding	that	was	done	at	C	and	C	Drugs	Vital	Care,	the	pharmacy	where	they	get	their	medications	filled.	Patients	who	had	received	compounded	medications,	either	for	themselves,	a	relative,	a	child,	or	pet	were	prompted	to	answer	more	detailed	questions	about	the	kinds	of	compounds	they	received,	what	they	understood	compounded	medications	to	be	for,	and	their	opinions	on	the	compounded	medications	they	had	received.	The	survey	then	asked	all	participants	about	their	perceptions	of	the	kind	of	small-scale	pharmacy	compounding	done	at	C	and	C	Drugs	Vital	Care,	and	of	the	New	England	Compounding	Center	fungal	meningitis	outbreak.	Levels	of	agreement	were	used	in	multiple	questions	to	describe	levels	of	familiarity	
Data	Management	
	 After	closing	data	collection,	surveys	completed	in	Qualtrics	were	downloaded	to	an	Excel	2013	spreadsheet.	On	this	spreadsheet,	investigators	entered	data	from	the	paper	surveys.	An	additional	field	was	added	to	the	spreadsheet	to	indicate	survey	numbers.	Numbers	on	the	spreadsheet	matched	
	 17	
numbers	that	were	placed	on	the	paper	survey	in	order	to	allow	the	investigators	to	cross-reference	papers	surveys	with	the	dataset	as	necessary.	After	all	paper	survey	data	were	entered,	the	data	was	uploaded	into	IBM	SPSS	Statistics	22	for	data	analysis.		
Analysis	
	 Sample	Description.	A	sample	description	was	generated	by	calculating	means,	frequencies	and	percentages	as	appropriate	for	each	demographic	characteristic	measured	among	participants.		 Prevalence	of	Compound	Use.	Frequencies	and	percentages	were	used	to	describe	the	prevalence	of	compound	use	among	respondents.	
	 Types	of	Compounds	Used/Reasons	for	Use.	Frequencies	and	percentages	were	used	to	describe	the	types	of	compounds	used	among	respondents	as	well	as	why	respondents	use	compounds.	A	Chi-Square	test	of	Independence	was	conducted	to	determine	if	the	type	of	compound	used	varied	according	to	patient	age.	
	 Knowledge	and	Familiarity.	Patient	knowledge	and	familiarity	were	analyzed	using	frequencies,	percentages,	and	Pearson	Chi	Square	tests	of	Independence.	Frequencies	and	percentages	were	used	to	analyze	questions	about	awareness	of	availability	of	compounding	at	C	and	C	Drugs	Vital	Care,	legal	uses	for	compounding,	and	familiarity	with	compounding	in	general,	as	well	as	the	New	England	Compounding	Center	(NECC)	event.	Chi	Square	analyses	were	conducted	to	test	for	differences	in	knowledge	between	respondents	who	received	compounds	and	those	who	did	not	receive	compounds	to	determine	whether	the	differences	in	their	knowledge	were	statistically	significant.		
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	 Satisfaction	and	Perceptions.	Patient	perceptions	were	analyzed	using	frequencies	and	means,	along	with	Chi	Square	tests	to	determine	statistically	significant	differences	between	groups.		Means	were	calculated	to	establish	an	average	satisfaction	or	agreement	score	on	questions	regarding	receipt	of	a	compound	and	patient-pharmacist	relationships	related	to	compounding.	Chi	Square	analysis	was	used	to	examine	statistically	significant	differences	between	those	who	did	and	did	not	receive	compounds	with	regard	to	how	supportive	they	were	of	pharmacy	compounding.			
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RESULTS	
Response	Rate		 Although	the	number	of	paper	surveys	and	survey	links	available	is	known	(175	and	1300,	respectively),	it	is	possible	that	individual	patients	may	have	received	the	survey	or	link	multiple	times	as	a	result	of	multiple	visits	to	the	pharmacy.	Therefore,	a	response	rate	was	not	able	to	be	calculated.	At	the	conclusion	of	data	collection,	81	electronic	and	60	paper	surveys	were	received.	Of	the	141	total	surveys	received,	7	were	not	included	in	data	analysis	due	to	the	surveys	being	incomplete.	Therefore,	a	resulting	134	total	surveys	were	used	for	data	analysis.	
Sample	Description			 In	order	to	better	understand	some	of	the	characteristics	of	respondents,	multiple	demographic	questions	were	asked.	Of	the	134	completed	surveys,	27	(20.1%)	were	completed	by	males,	and	107	(79.9%)	were	completed	by	females.	The	minimum	age	to	complete	the	survey	was	18	years	old.	Participant	ages	ranged	from	18	to	80	years	of	age,	with	a	mean	age	of	about	50	(49.59)	years.	The	majority	of	respondents	reported	their	race	as	Caucasian,	with	129	of	134	(96.3%)	respondents	designating	it	as	their	nationality.	Respondents’	highest	levels	of	education	were	more	varied,	with	Bachelor’s	degree	and	some	college	completed	being	the	most	common	responses	at	32.1%	and	23.9%,	respectively.	In	terms	of	
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employment	status,	47.8%	of	respondents	had	full-time	jobs.		When	asked	about	their	total	household	income,	only	129	of	the	134	respondents	chose	to	answer	the	question.	Most	of	the	respondents	reported	a	total	household	income	of	$80,000	per	year	or	more.	Additional	sample	characteristics	can	be	found	in	Table	1.			 Table	1:	Demographic	Characteristics	
Nationality	 Number	of	Respondents	(%)						African-America						American	Indian/Alaska	Native						Asian/Asian	Indian						Caucasian	(white)						Hispanic							Native	Hawaiian/Pacific	Islander						Other	
					2	(1.5)						0	(0)						1	(0.7)						129	(96.3)						2	(1.5)						0	(0)						0	(0)	
Highest	Level	of	Education	 Number	of	Respondents	(%)						Some	grade	school						Some	high	school						High	school	diploma	or	GED						Some	college						Vocational	degree						Associate’s	degree						Bachelor’s	degree						Master’s	degree						Doctoral	degree						Professional	degree	(MD,	etc.)	
					0	(0)						3	(2.2)						26	(19.4)						32	(23.9)						4	(3.0)						5	(3.7)						43	(32.1)						11	(8.2)						5	(3.7)						5	(3.7)	
Employment	Status	 Number	of	Respondents	(%)						Full-time						Part-time						Unemployed						Student						Retired						Disabled	
					64	(47.8)						20	(14.9)						11	(8.2)						9	(6.7)						24	(17.9)						6	(4.5)	
Total	Household	Income*	 Number	of	Respondents	(%)						Less	than	$10,000						$10,000	to	$19,999	 					4	(3.0)						9	(6.7)	
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					$20,000	to	$29,999						$30,000	to	$39,999						$40,000	to	$49,999						$50,000	to	$59,999						$60,000	to	$69,999						$70,000	to	$79,999						$80,000	to	$89,999						$90,000	to	$99,999						$100,000	to	$149,999						$150,000	or	more	
					6	(4.5)						7	(5.2)						7	(5.2)						6	(4.5)						9	(6.7)						5	(3.7)						11	(8.2)						10	(7.5)						30	(22.4)						25	(18.7)	*Total	number	of	respondents	=	129	
	
Prevalence	of	Compound	Use		 Respondents	were	asked	to	indicate	if	they	themselves,	a	spouse	or	significant	other,	a	child,	a	pet,	or	no	one	in	their	household	had	ever	received	a	compounded	medication.	Respondents	were	asked	to	select	all	answers	that	applied.	The	most	common	responses	were	“myself”	and	“no	one,”	with	frequencies	of	60	and	50	responses,	respectively.	There	were	a	total	of	83	surveys	that	indicated	that	they	either	received	a	compound	themselves,	or	had	a	household	member	that	got	one,	and	51	respondents	indicated	no	one	in	their	household	had	ever	received	a	compounded	medication.	Other	data	pertaining	to	the	distribution	of	association	with	compounds	can	be	found	in	Table	2.			 The	respondents	that	reported	having	a	household	association	with	compounded	medications	were	then	asked	to	complete	an	additional	set	of	questions.	The	sample	size	for	these	questions	was	83	(representing	the	number	of	respondents	indicating	that	someone	in	their	household	has	used	a	compound),	rather	than	134,	used	in	previous	questions.	They	were	asked	to	write	in	the	
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number	of	different	compounds	received	in	the	last	year,	not	including	refills.	Responses	varied	from	zero	to	ten.	A	response	of	zero	indicated	that	they	had	gotten	compounds	before,	just	not	in	the	last	year.	The	majority	of	participants	received	one	or	two	compounds	in	the	last	year,	with	those	percentages	being	24.6%	and	17.9%	of	the	83-respondent	sample	size,	respectively.	Additional	data	on	the	number	or	prescriptions	picked	up	in	the	last	year	by	those	patients	that	got	compounded	medications	can	be	found	in	Table	3.			 Table	2:	Recipients	of	Compounds	
Compound	Recipient	 Number	of	Respondents	(%)						Myself						Spouse	or	significant	other						Child						Pet						No	one	
					60	(44.8)						17	(12.7)						15	(11.2)						17	(12.7)						50	(37.3)			 Table	3:	Number	of	Compounds	Received	in	the	Past	Year	
Number	of	Compounds	 Number	of	Respondents	(%)						0						1						2						3						4						5						6						7						8						9						10	
					15	(18.1)						33	(39.8)						24	(28.9)						6	(7.2)						3	(3.6)						1	(1.2)						0	(0)						0	(0)						0	(0)						0	(0)						1	(1.2)	
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		 Patients	who	used	compounds	in	their	household	were	also	asked	to	indicate	how	many	of	their	compounded	medications	are	covered	by	insurance	(in	other	words,	not	run	for	a	“cash	price”).	Ten	compound	users	(12%)	indicated	that	they	did	not	have	insurance	while	37	(46%)	indicated	that	none	of	their	compounds	were	covered	by	insurance.	Twenty-one	respondents	(26%)	indicated	that	all	of	their	compounds	were	covered	by	insurance.	A	small	number	of	respondents	(13)	indicated	that	some	of	their	compounds	are	covered	by	insurance.	
Types	of	Compounds	Used/Reasons	for	Use	Question	12	asked	those	participants	that	got	compounds	in	their	household,	what	kinds	of	compounds	they	get,	or	what	the	indications	are	for	them.	Of	the	83	who	got	compounds,	33.7%	indicated	that	they	or	someone	in	their	household	got	a	compound	that	was	a	bioidentical	hormone	cream	or	gel,	followed	by	21.7%	respondents	having	bought	a	compounded	medication	for	their	pet.	Other	dermatologic	or	anesthetic	creams	were	also	common,	with	16.9	and	15.7%,	respondents	reporting	use,	respectively.	Additional	data	on	what	kinds	of	compounds	respondents	reported	receiving	can	be	found	in	Table	4.		Further	analysis,	using	the	Chi	Square	test	of	Independence	was	performed	to	determine	for	each	type	of	compound	listed	in	Table	4,	if	there	was	a	difference	in	frequency	of	usage	based	on	age.	To	conduct	the	analysis,	age	ranges	were	used.	Based	on	their	reported	age,	respondents	were	categorized	into	four	age	groups	as	utilized	by	the	Census	Bureau	(18-24,	24-44,	45-64,	and	65+).	Not	surprisingly,	
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respondents	in	the	45-64	age	group	reported	using	more	bioidentical	hormone	creams	than	respondents	in	any	other	age	group,	X2	(3,	N	=	134)	=	18.4,	p	<	.05.			 Table	4:	Types	of	Compounds	Received	
Kinds	of	Compounds	Received	 Number	of	Respondents	(%)						Bioidentical	hormone	capsules						Bioidentical	hormone	creams/gels						Nasal	sprays	or	irrigations						Infusible	antibiotics	or	TPNs						Anesthetic	(pain	relief/numbing)						Lip	balms	(cold	sores)						Dermatologic	creams						Gastroenterological	(domperidone)						Magic	Mouthwash						Pet	medications						Trimix						Vancomycin						Troches	or	lollipops						Suppositories						Eye	or	ear	drops	
					11	(13.3)						28	(33.7)						5	(6)						4	(4.8)						13	(15.7)						4	(4.8)						14	(16.9)						5	(6)						5	(6)						18	(21.7)						1	(1.2)						2	(2.4)						0	(0)						2	(2.4)						3	(3.6)			 Those	patients	who	had	received	compounded	medications	themselves	or	in	their	household	were	asked	to	indicate	why	they	received	a	compounded	medication.	As	indicated	by	the	information	above,	the	most	common	reasons	for	using	compounds	were	“individualized	hormone	combinations”	and	“drug	not	available	for	pharmacy	to	order,”	with	34.9%	and	30.1%	of	respondents	indicating	those	as	their	reasons	for	getting	compounds,	respectively.	Another	common	reason	was	to	get	the	drug	product	in	the	right	dosage	form,	chosen	by	26.5%	of	respondents.	More	than	one	reason	could	be	chosen,	and	some	may	be	related	to	the	
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same	compounded	medication	used	by	the	patient.	Additional	data	can	be	found	in	Table	5.			 Table	5:	Respondent	Reasons	for	Using	Compounds	
Reasons	for	Using	Compounds	 Number	of	Respondents	(%)						Individualized	hormone	combinations						Individualized	dosages	for	a	child						Individualized	dosages	for	a	pet						Drug	not	available	for	pharmacy	to	order						Proper	dosage/strength	not	available	to	order						More	personal	patient-pharmacist	relationship						Allergies	to	commercially	available	drugs						Combine	multiple	medications	into	a	single	dose						Avoid	unwanted	ingredients						Dosage	form	needs	(cream	vs	tablet)						Personal	preference						Insurance	reasons						Addition	of	flavoring	
					29	(34.9)						10	(12.0)						17	(20.5)						25	(30.1)						12	(14.5)						5	(6.0)						4	(4.8)						16	(19.3)						13	(15.7)						22	(26.5)						9	(10.8)						2	(2.4)						4	(4.8)	
	
Knowledge	and	Familiarity		 Participants	were	asked	if	they	were	aware	that	C	and	C	Drugs	Vital	Care	offered	compounded	medications.	Of	the	134	respondents,	118	respondents,	or	88.1%	were	aware	that	compounded	prescriptions	were	an	option.	Of	these	118	respondents	aware	of	compounded	prescriptions	at	the	pharmacy,	81	of	those	respondents,	or	68.6%,	had	used	compounds	in	their	household.	This	was	significantly	higher	than	respondents	who	did	not	use	compounds	in	their	household	to	be	aware	of	compounds	being	made	at	the	pharmacy,	X2	(1,	N	=	134)	=	15.0,	p	<	.05.	
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	 All	respondents	were	asked	to	indicate,	from	a	list	of	options,	what	they	thought	were	legally	acceptable	uses	for	compounded	medications.	Participants	could	select	as	many	of	the	ten	options	that	they	thought	were	legally	acceptable	reasons	for	getting	medications	compounded.	The	most	commonly	selected	reasons	were	“dosage	form	needs”	and	to	“combine	medications	into	a	single	dose,”	with	90	and	79	people	choosing	the	options,	respectively.	Further	information	on	frequencies	for	each	of	the	options	can	be	found	in	Table	6.	Additionally,	Table	6	outlines	which	of	the	uses	are	legally	acceptable,	and	which	are	not.		 The	frequencies	for	each	option	were	then	split	into	those	who	reported	themselves,	or	someone	else	in	their	house	getting	a	compounded	medication,	and	those	who	had	no	one	in	their	household	receive	a	compounded	medication.	The	frequency	breakdown	of	the	ten	options	between	those	who	got	compounds,	and	those	who	did	not	can	be	found	in	Figure	1.	There	was	a	statistically	significant	difference	between	those	who	received	compounds	and	those	who	did	not	for	“drug	not	available	for	pharmacy	to	order”	(X2	(1,	N	=	134)	=	5.4,	p	<	.05)	and	“proper	dosage	not	available	for	pharmacy	to	order”	(X2	(1,	N	=	134)	=	5.6,	p	<	.05).	Among	these,	those	who	used	compounded	medications	in	their	household	thought	the	reasons	mentioned	above	were	legally	acceptable	uses	more	frequently	than	those	who	had	not	gotten	a	compound.					
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Table	6:	Legally	Acceptable	Uses	for	Compounded	Medications	
Potential	Uses	 Number	of	
Respondents	(%)	
Legal	Use?						Drug	not	available	for	pharmacy	to	order						Proper	dosage	not	available	to	order						Allergy	to	commercially	available	version						Combine	medications	into	a	single	dose						Avoid	unwanted	ingredients						Personal	preference						Children’s	dosing	needs						Drug	shortages						Dosage	form	needs	(cream	vs.	tablet)						Addition	of	flavoring	
63	(47)	66	(49.3)	61	(45.5)	79	(59)	70	(52.2)	41	(30.6)	71	(53)	31	(23.1)	90	(67.2)	53	(39.6)	
No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes		Figure	1:	Legally	Acceptable	Compound	Use	Perceptions	
			 All	respondents	were	to	indicate	their	level	of	knowledge	about	the	outbreak	of	fungal	meningitis	that	was	traced	back	to	the	New	England	Compounding	Center	
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(NECC).	The	answer	choices	ranged	from	“extremely	familiar”	to	“not	at	all	familiar.”	The	majority	of	respondents	reported	being	“not	at	all	familiar,”	with	78%	choosing	this	option.	A	summary	of	responses	can	be	found	in	Figure	2.			 Figure	2:	Familiarity	with	NECC	Outbreak	
			 All	respondents	were	asked	about	their	familiarity	with	pharmacy	compounding,	from	“extremely	familiar”	to	“not	at	all	familiar.”	While	C	and	C	Drugs	Vital	Care	dispenses	a	large	amount	of	compounded	medications,	about	37%	of	respondents	reported	being	moderately	familiar	and	almost	30%	reported	being	only	slightly	familiar	with	compounding.	A	summary	of	responses	can	be	found	in	Figure	3.		
Extremely	2%	 Very,	7,	5%	 Moderately,	9,	7%	Slightly,	11,		8%	
Not	at	All	78%	
HOW	FAMILIAR	ARE	YOU	WITH	THE	NEW	
ENGLAND	COMPOUNDING	CENTER	FUNGAL	
MENINGITIS	OUTBREAK?	
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	 Additional	analysis	was	done	to	determine	if	the	familiarity	with	compounded	medications	changed	with	the	personal	or	household	use	of	a	compound,	and	then	further	to	determine	if	the	relation	to	the	person	that	received	the	compound	changed	peoples’	familiarity	with	the	topic.	When	respondents	were	divided	into	only	two	groups,	one	having	not	received	a	compounded	medication	within	their	household	and	the	other	including	all	respondents	that	either	had	a	household	member	receive	a	compounded	medication,	or	they	personally	had	gotten	a	compound,	a	Pearson	Chi	Square	test	of	Independence	was	performed	to	examine	whether	or	not	there	was	a	difference	in	familiarity	between	the	two	groups.	There	was	found	to	be	a	statistical	significant	difference	between	the	two	groups,	with	the	group	who	had	at	least	received	a	household	compounds	being	more	familiar	with	compounded	medications,	X2	(4,	N	=	134)	=	35.3,	p	<	.05.	Of	the	“receives	compounds”	group,	70%	of	those	included	in	the	group	were	“moderately	familiar”	or	more	with	compounded	medications.	In	the	group	that	did	not	get	compounds,	76%	of	respondents	reported	being	“not	at	all,”	or	only	“slightly”	familiar	with	compounding.	Additional	data	can	be	found	in	Figures	4	and	5.			 A	third	analysis	was	done	to	examine	whether	familiarity	changed	depending	on	the	particular	person	that	received	the	compound.	Respondents	were	split	into	three	groups:	those	who	claimed	no	contact	with	compounded	prescriptions,	those	who	said	they	had	a	household	member	who	received	a	compounded	medication,	and	those	who	personally	received	compounded	medications,	and	may	have	an	additional	household	member	receive	them	as	well.	A	Pearson	Chi	Square	test	of	Independence	was	performed	on	the	three	groups	and	a	statistically	significant	
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difference	in	familiarity	was	found	between	the	three	groups,	X2	(8,	N	=	134)	=	39.8,	p	<	.05.	Higher	levels	of	familiarity	were	more	often	found	in	the	group	with	personal	receipt	of	a	compound,	and	lowest	familiarity	in	those	who	had	no	connection	to	compounded	medications.			 Figure	3:	Familiarity	with	Pharmacy	Compounding	
		 							
Extremely	6%	 Very	10%	
Moderately	37%	Slightly		30%	
Not	at	All	17%	
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PHARMACY	COMPOUNDING?	
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Figure	4:	Familiarity	with	Pharmacy	Compounding	among	Compound	Users	
		 Figure	5:	Familiarity	with	Pharmacy	Compounding	among	Compound	Non-Users	
			
Extremely	7%	 Very	14%	
Moderately	49%	
Slightly	25%	
Not	at	All	5%	
HOW	FAMILIAR	ARE	YOU	WITH	
PHARMACY	COMPOUNDING?	(GETS	
COMPOUNDS)	
Extremely	4%	 Very	2%	 Moderately	18%	
Slightly	38%	
Not	at	All	38%	
HOW	FAMILIAR	ARE	YOU	WITH	
PHARMACY	COMPOUNDING?	(DOES	NOT	
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Satisfaction	and	Perceptions		 Respondents	who	received	compounds	were	asked	a	series	of	questions	regarding	their	satisfaction	with	compounded	medications.	This	first	set	of	questions	was	product-focused.	They	were	asked	to	rate	their	satisfaction	on	a	linear	numeric	scale,	with	“1”	being	“not	at	all	satisfied,”	and	“5”	being	“very	satisfied.”	The	average	answers	to	the	questions	were	high,	with	the	highest	being	4.68	out	of	5	for	the	safety	and	quality,	and	the	lowest	being	4.10	out	of	a	possible	5	for	the	cost	of	the	compounds.	Additional	data	on	patient	satisfaction	with	compounds	can	be	found	in	Table	7.			 Other	questions	were	asked	to	assess	how	respondents	that	received	compounded	medications	felt	about	more	subjective	matters,	like	relationships	with	their	pharmacist.	These	questions	used	a	Likert	scale	with	“1”	being	“strongly	disagree,”	and	a	score	of	“5”	being	“strongly	agree.”	Average	scores	were	not	as	high	as	the	satisfaction	questions	asked	in	the	section	before,	but	still	comparatively	high,	ranging	from	3.53	to	3.90,	out	of	a	possible	5.	Additional	data	can	be	found	in	Table	8.			 	 	
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Table	7:	Respondent	Satisfaction	with	Compounded	Medications*	
	 Frequency	(%)	 Average	
(SD)	
	 1	 2	 3	 4	 5	 	How	satisfied	are	you,	in	general,	with	your	compound?	 2	(2.5)	 0	(0)	 3		(3.8)	 13		(16.5)	 61		(77.2)	 4.66		(0.783)	How	satisfied	are	you	with	the	cost	of	your	compound?	 3		(3.8)	 4	(5.1)	 13	(16.5)	 21	(26.6)	 38	(48.1)	 4.10	(1.093)	How	satisfied	are	you	with	the	quality	of	your	compound?	 1	(1.3)	 2	(0)	 4	(5.1)	 13	(16.5)	 61	(77.2)	 4.68	(0.690)	How	satisfied	are	you	with	the	ease	of	use	of	your	compound?	 0	(0)	 2	(2.5)	 6	(7.6)	 13	(16.5)	 58	(73.4)	 4.61	(0.741)	How	satisfied	are	you	with	the	safety	of	your	compound?	 0	(0)	 1	(1.3)	 4	(5.1)	 14	(17.9)	 59	(75.6)	 4.68	(0.634)	How	satisfied	are	you	with	the	appearance	of	your	compound?	 1	(1.3)	 0	(0)	 4	(5.1)	 14	(17.7)	 60	(75.9)		 4.67	(0.693)	How	satisfied	are	you	with	the	packaging	of	your	compound?	 0	(0)	 0	(0)	 4	(5.1)	 19	(24.1)	 56	(70.9)	 4.66	(0.575)	How	satisfied	are	you	with	the	convenience	of	having	a	compound?	 1	(1.3)	 0	(0)	 6	(7.6)	 13	(16.5)	 59	(74.7)	 4.63	(0.737)	How	satisfied	are	you	with	the	performance	of	your	compound?	 1	(1.3)	 0	(0)	 6	(7.6)	 13	(16.5)	 59	(74.7)	 4.63	(0.737)	*	1	=	not	at	all	satisfied	and	5	=	very	satisfied					
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Table	8:	Respondent	Agreement	with	Statements*	
	 Frequency	(%)	 Average	
(SD)	
	 1	 2	 3	 4	 5	 	I	prefer	compounded	medications	over	manufactured,	commercially	available	medications	
0	(0)	 6	(7.2)	 46	(55.4)	 12	(14.5)	 19	(22.9)	 3.53	(0.928)	
Getting	compounded	medications	leads	to	a	deeper	and	more	personal	relationship	with	my	pharmacist	
3	(3.6)	 5	(6.0)	 32	(38.6)	 25	(30.1)	 18	(21.7)	 3.60	(1.011)	
Getting	compounded	medications	leads	to	a	more	patient-centered,	rather	than	drug-centered	relationship	with	my	pharmacist.		
1	(1.7)	 4	(4.8)	 25	(30.1)	 25	(30.1)	 28	(33.7)	 3.90	(0.970)	
*	1	=	strongly	disagree	and	5	=	strongly	agree		 Respondents	were	also	asked	about	their	support	for	compounded	medications.	Answer	choices	were	the	same	as	the	question	before	it	that	asked	about	familiarity,	ranging	from	“extremely	supportive”	to	“not	at	all	supportive.”	There	was	also	a	sixth	option,	“I	don’t	know;	I	have	never	heard	about	pharmacy	compounding	before	taking	this	survey.”	The	majority	of	respondents	were	supportive	of	compounds,	with	36%	of	respondents	being	“very	supportive,”	and	34%	being	“extremely	supportive.”	Additional	data	can	be	found	in	Figure	6.			 Additional	analysis	was	done	to	determine	if	those	who	had	received	a	compound	within	the	family	were	more	supportive	of	compounded	medications	
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than	those	who	had	not.	The	respondents	were	split	into	two	groups:	those	who	had	compound	use	in	the	household,	and	those	who	had	no	connection	to	compounded	medications.	A	statistically	significant	difference	was	found	between	the	two	groups,	with	those	having	a	household	connection	to	compounded	medications	being	more	supportive	of	compounded	medications,		X2	(4,	N	=	134)	=	34.4,	p	<	.05	The	group	that	did	not	get	compounds	reported	more	“I	don’t	know”	and	“moderately	supportive”	answers	than	the	group	that	received	compounds.	No	participant	in	either	group	reported	being	unsupportive	of	compounded	medications.	Further	data	on	the	differences	in	answers	between	the	two	groups	can	be	found	in	Figures	7	and	8.			 Figure	6:	Support	for	Pharmacy	Compounds	(All	Respondents)	
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Figure	7:	Support	for	Pharmacy	Compounds	by	Compound	Users	
		 Figure	8:	Support	for	Pharmacy	Compounds	by	Compound	Non-Users	
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DISCUSSION	
Discussion	of	Findings		 This	study	aimed	to	measure	patients’	use,	knowledge	and	perceptions	of	small-scale	pharmacy	compounding	at	an	independent	compounding	pharmacy	in	Mandeville,	Louisiana,	C	and	C	Drugs	Vital	Care.	About	20%,	of	the	pharmacy’s	business	is	comprised	of	compounded	medications,	and	therefore	they	are	widely	used	in	the	store’s	patient	population,	with	some	patients	using	more	than	one	unique	compound.	Anecdotally,	many	of	the	patients	have	gotten	to	know	the	compounding	pharmacist	and	tend	to	be	very	supportive	of	him,	whether	they	get	compounds	or	not.	Specifically,	positive	word-of-mouth,	is	thought	to	be	a	reason	that	new	patients	come	to	C	and	C	Drugs	Vital	Care.	Many	of	the	findings	in	this	study	may	be	explained	by	the	support	for	the	compounding	pharmacist	and	his	practice,	but	further,	in-depth,	longitudinal,	quantitative,	and	qualitative	research	is	needed	to	confirm	these	findings.		For	example,	all	respondents	were	asked	to	report	their	familiarity	with,	and	supportiveness	of,	pharmacy	compounding.	While	there	were	significant	differences	in	familiarity	and	support	between	those	who	did	and	did	not	have	a	connection	to	compounded	medications,	even	those	who	did	not	get	compounded	medications	were	still	familiar	with	or	supportive	of	the	practice.	Indeed,	comments	provided	by	
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some	of	the	respondents	at	the	end	of	the	survey	reiterated	these	findings.	For	example,	one	respondent	noted:		“My	38	year	daughter	has	many	medical	problems,	and	compounding	meds	is	extremely	valuable	to	her	due	to	many	allergies	to	many	ingredients	that	are	used,	although	in	small	amounts,	in	many	drugs,	causing	terrible	side	effects.		Can	get	just	an	effective	med	thru	compounding.”		Another	respondent	less	familiar	with	compounding	noted:		 “I	know	very	little	about	pharmaceutical	compounding.		I	assume	that	it	was	more	common	prior	to	the	mass	production	of	medications	in	recent	times.		Depending	on	the	circumstances,	I	would	think	that	there	is	still	and	will	continue	to	be	a	need	to	pharmaceutical	to	better	serve	patients.”				In	light	of	these	findings,	the	characteristics	of	the	study	sample	should	not	be	ignored.	The	vast	majority	of	the	respondents	described	themselves	as	Caucasian,	highly	educated,	and	making	high	incomes.	Perhaps	this	sample	is	a	reflection	of	the	local	population,	or	it	could	be	a	self-selection	phenomenon.	In	other	words,	this	pharmacy	may	attract	this	type	of	patient	population	because	it	does	make	compounds	that	may	be	more	expensive	and	sometimes	not	covered	by	insurance,	or	this	type	of	population	may	be	more	desiring	of	compounded	
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products.		That	said,	there	was	still	concern	expressed	by	a	respondent	in	her	comment	about	the	cost	of	compounded	medications:		“Why	is	it	so	expensive?		I	used	to	get	my	compounding	cream	for	$35	and	now	it's	over	$200,	therefore	I	no	longer	get	it	because	I	can't	afford	it,	although	it	is	like	"magic"	cream	for	my	pain.		It	really	helps	my	pain	condition	greatly.”		Indeed,	nearly	56%	of	the	83	respondents	reported	not	having	insurance	or	insurance	not	covering	any	of	their	medications.	Interestingly,	those	that	reported	using	a	compounded	medication	in	their	household	more	often	reported	that	a	“drug	not	available	for	the	pharmacy	to	order”	and	“proper	dosage	not	available	for	the	pharmacy	to	order”	were	legally	acceptable	reasons	to	make	a	compounded	medications.	While	a	proper	dosage	not	being	available	is	a	legitimate	reason	to	compound	a	medication,	a	medication	not	being	available	for	the	pharmacy	to	order	is	not.	Additionally,	41	of	the	134	total	respondents	(approximately	31%)	indicated	that	they	believed	personal	preference	was	a	legally	acceptable	use	for	a	compounded	medication.	While	not	statistically	significant,	it	was	found	that	more	respondents	who	did	not	use	compounds	in	their	household	thought	personal	preference	was	legally	acceptable	than	did	respondents	who	did	use	compounded	medications	in	their	household.	In	general,	this	suggests	that	patient	education	on	appropriate	reasons	for	making	compounded	medications	
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may	be	worthwhile.	However,	respondents’	interpretation	of	the	questions	should	be	taking	into	consideration	when	exploring	these	findings.	Another	interesting	finding	was	the	lack	of	knowledge	of	the	NECC	event	that	happened	only	a	few	years	ago.	The	reported	outcome	may	have	been	a	function	of	how	the	question	was	asked.	Many	patients	may	have	remembered	hearing	about	the	many	cases	of	deadly	fungal	meningitis	that	were	contracted	from	an	injection,	but	they	may	not	have	known	that	the	NECC	was	the	organization	responsible	for	compounding	those	tainted	medications.		
Limitations		 The	topic	of	pharmaceutical	compounds	and	their	perception	by	the	surrounding	patient	population	can	be	greatly	affected	by	the	setting,	which	is	the	main	limitation	of	this	study.	The	survey	was	only	administered	at	a	single	pharmacy,	making	it	a	convenience	sample,	rather	than	one	that	is	truly	representative	of	the	whole	state	or	country.	Community	perceptions	may	differ	in	New	England,	as	the	NECC	outbreak	was	a	closer	threat	and	may	have	turned	many	patients	off	of	compounding,	or	in	a	city	that	does	not	have	a	pharmacy	that	offers	compounded	medications,	in	which	case	there	is	a	lack	of	knowledge	of	them.	By	using	only	one	community	to	draw	data	from,	and	by	choosing	a	pharmacy	that	was	very	involved	in	the	practice	of	pharmacy	compounding,	the	study	is	not	generalizable	to	the	rest	of	the	United	States	or	all	patient	populations.		The	motivation	of	patients	within	the	sample	may	also	affect	the	generalizability.	Participation	was	voluntary,	so	it	can	be	expected	that	self-selection	bias	may	result	in	a	much	higher	ratio	of	patients	who	get	compounded	medications	
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participating.	The	results	were	not	adversely	swayed	in	this	study,	but	there	was	a	very	large	percentage	of	responses	that	were	from	patients	with	a	connection	to	compounded	medications.	Pharmacy	patients	may	have	also	felt	more	inclined	to	complete	the	survey	when	they	saw	that	their	participation	would	benefit	one	of	the	employees,	someone	they	knew	personally,	rather	than	a	survey	that	was	conducted	by	someone	they	did	not	know.		
Conclusions	and	Implications		 Overall,	both	groups	of	participants,	those	who	got	compounds	themselves	or	had	a	household	member	who	received	a	compound,	and	those	who	had	no	ties	to	compounds,	had	positive	perceptions	of	compounded	medications,	and	were	familiar	with	the	practice.	Even	those	who	did	not	have	any	connection	to	compounded	medications	appeared	familiar	with	the	practice	of	compounding	medications.	Again,	this	may	be	due	to	the	culture	of	C	and	C	Drugs	Vital	Care	and	the	efforts	by	the	compounding	pharmacist	to	create	an	atmosphere	and	business	that	promotes	pharmacy	compounding	and	positive	perceptions	of	it	by	the	patients.	However,	further,	in-depth,	longitudinal,	quantitative,	and	qualitative	research	is	needed	to	confirm	these	findings.	Future	confirmation	of	these	findings	has	significant	implications	for	pharmacists,	and	how	the	culture	they	create	in	their	pharmacy	can	lead	to	enhanced	knowledge,	positive	perceptions,	and	increased	satisfaction	among	patients.	This	type	of	work	could	be	translated	to	other	compounding	practices	or	any	other	patient-oriented	pharmacy	service	such	as	medication	therapy	management	(MTM).		
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Appendix	B:	Cover	Letter	for	Paper	Survey	Dear	Patient,			My	name	is	Alix	Cawthon,	and	I	am	a	pharmacy	student	at	Ole	Miss.	This	summer	and	fall,	I	am	conducting	a	research	survey	through	the	Sally	McDonnell	Barksdale	Honors	College,	and	I	am	asking	for	your	participation.	This	survey	should	take	no	more	than	7	or	8	minutes	of	your	time.	It	includes	various	demographic	questions,	but	mainly	focuses	on	your	knowledge	and	perceptions	of	pharmacy	compounding,	such	as	the	kind	done	at	C	and	C	Drugs	Vital	Care.	We	are	inviting	all	customers	to	participate,	whether	you	get	compounded	medications	or	not.	Your	willingness	to	participate	in	this	research	will	help	me	better	understand	patients’	understanding	and	attitude	toward	small-scale	pharmaceutical	compounding.			Please	keep	in	mind	that	your	participation	in	this	survey	is	entirely	voluntary.	Your	completion	of	this	survey	does	not	affect	your	patronage	at	this	pharmacy,	or	with	any	of	its	employees.	Your	responses	will	remain	completely	anonymous	and	will	be	examined	along	with	other	respondents’	surveys.			This	study	has	been	reviewed	by	the	University	of	Mississippi’s	Institutional	Review	Board	(IRB).	The	IRB	has	determined	that	this	study	fulfills	the	human	research	subject	protections	obligations	required	by	the	state	and	federal	law	and	University	policies.	If	you	have	any	questions,	please	contact	the	IRB	at	(662)	915-7482.		If	you	have	any	questions	about	the	research	project	specifically,	feel	free	to	contact	me	at	macawtho@go.olemiss.edu,	or	my	advisor,	Dr.	Erin	Holmes,	at	erholmes@olemiss.edu,	or	(662)	915-5914.		Thank	you	in	advance	for	your	participation.			Sincerely,		Alix	Cawthon	
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Appendix	C:	Cover	Letter	for	Electronic	Survey		Dear	Patient,			My	name	is	Alix	Cawthon,	and	I	am	a	pharmacy	student	at	Ole	Miss.	This	summer	and	fall,	I	am	conducting	a	research	survey	through	the	Sally	McDonnell	Barksdale	Honors	College,	and	I	am	asking	for	your	participation.	This	survey	should	take	no	more	than	7	or	8	minutes	of	your	time.	It	includes	various	demographic	questions,	but	mainly	focuses	on	your	knowledge	and	perceptions	of	pharmacy	compounding,	such	as	the	kind	done	at	C	and	C	Drugs	Vital	Care.	We	are	inviting	all	customers	to	participate,	whether	you	get	compounded	medications	or	not.	Your	willingness	to	participate	in	this	research	will	help	me	better	understand	patients’	understanding	and	attitude	toward	small-scale	pharmaceutical	compounding.	You	can	access	the	survey	by	typing	the	link	below	into	your	internet	browser:		
http://tinyurl.com/n7nj89l		Please	keep	in	mind	that	your	participation	in	this	survey	is	entirely	voluntary.	Your	completion	of	this	survey	does	not	affect	your	patronage	at	this	pharmacy,	or	with	any	of	its	employees.	Your	responses	will	remain	completely	anonymous	and	will	be	examined	along	with	other	respondents’	surveys.			This	study	has	been	reviewed	by	the	University	of	Mississippi’s	Institutional	Review	Board	(IRB).	The	IRB	has	determined	that	this	study	fulfills	the	human	research	subject	protections	obligations	required	by	the	state	and	federal	law	and	University	policies.	If	you	have	any	questions,	please	contact	the	IRB	at	(662)	915-7482.		If	you	have	any	questions	about	the	research	project	specifically,	feel	free	to	contact	me	at	macawtho@go.olemiss.edu,	or	my	advisor,	Dr.	Erin	Holmes,	at	erholmes@olemiss.edu,	or	(662)	915-5914.		Thank	you	in	advance	for	your	participation.			Sincerely,		Alix	Cawthon	
	
	
	
	
	
	
